Investors were thrilled by the Phase IIa clinical trial results of NeuroDerm’s continuously delivered Parkinson’s candidates that are administered via a belt or patch pump, offering patients an alternative to traditional orally delivered levodopa, which is notorious for its fluctuating concentrations in the blood.
The company’s stock price more than doubled to $18 upon the year-end news of the positive results. The shares now sell for about $15.50 on the Nasdaq, but that’s still above last year’s IPO price of $10 and its December 2014 low of $6.
The company reported that the two candidates, ND0612L and ND0612H, demonstrated safety and were tolerated by the patients. Moreover, the fluctuations in levodopa plasma levels were lower compared to that achieved by oral administration of the drug. For that feat, thank the candidates’ novel form of continuous drug delivery, which is designed to overcome levodopa’s short-half life and provide a steady level of the drug in the body.
ND0612L, for moderate Parkinson’s, is delivered via a small belt-worn pump similar to that used to provide insulin to diabetics, or a patch pump, NeuroDerm explains on its website. ND0612H is for severe cases and is only available via belt pump. All modes of administration are subcutaneous forms of delivery.
Using approved therapies, continuous delivery of levodopa can only be achieved by an invasive surgery to permanently implant a tube into the duodenum (the upper part of the small intestine), NeuroDerm says.
Comentarios recientes